Guinea-Pig Anaphylaxis: Protection by BN-52021, a PAF-Receptor Antagonist

2015 ◽  
pp. 11-18
Author(s):  
F. Berti ◽  
G. Rossoni ◽  
L. Villa
Keyword(s):  
Guinea Pig ◽  
Receptor Antagonist ◽  
Paf Receptor ◽  
Paf Receptor Antagonist

Scorpion venom-induced neutrophilia is inhibited by a PAF receptor antagonist in the rat

2000 ◽  
Vol 67 (4) ◽  
pp. 515-519 ◽  
Author(s):  
Cynthia M. Borges ◽  
Micheline R. Silveira ◽  
M. Aparecida ◽  
C. L. Beker ◽  
Lineu Freire-Maia ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Scorpion Venom ◽  
Paf Receptor ◽  
Paf Receptor Antagonist

Platelet-activating factor antagonism and streptokinase-induced hypotension in clinical acute myocardial infarction

2001 ◽  
Vol 100 (6) ◽  
pp. 601-607 ◽  
Author(s):  
Roger TAYLOR ◽  
Daniel FATOVICH ◽  
Thomas HITCHCOCK ◽  
Catherine MORRISON ◽  
Lloyd CURTIS
Keyword(s):  
Myocardial Infarction ◽  
Blood Pressure ◽  
Acute Myocardial Infarction ◽  
Receptor Antagonist ◽  
Platelet Activating Factor ◽  
Systolic Pressure ◽  
Induced Hypotension ◽  
Paf Receptor ◽  
Double Blinded ◽  
Paf Receptor Antagonist

Continuing efforts are being made to improve thrombolytic therapy for acute myocardial infarction (AMI). The rate of streptokinase (SK) infusion is commonly limited by the hypotension that is induced. If this could be avoided, an accelerated regimen of SK could be given, analagous to that used for other thrombolytic agents such as alteplase. The mechanism of the SK-induced hypotension is unknown, but there is some evidence that platelet-activating factor (PAF) plays a role. The potent PAF receptor antagonist lexipafant (10 mg) (n = 35), or matching placebo (n = 36), was administered intravenously over 5 min, in a randomized double-blinded protocol, to consecutive patients about to receive SK for AMI; all but three had inferior MI, because of the preference for strategies other than SK therapy in patients with anterior MI. The rate of infusion of SK was set to give 1.5×106 units over 30 min, anticipating significant hypotension. Blood pressure fell sharply over the first 10 min of SK administration. The maximum fall in systolic blood pressure occurred between 8 and 12 min, and averaged 43±28 mmHg (mean±S.D.) and 40±26 mmHg in patients given placebo and lexipafant respectively. Systolic pressure having fallen to < 90 mmHg, according to protocol the SK administration rate was reduced in 21 of 36 (58%) of patients given placebo and in 19 of 35 (54%) of patients given lexipafant. The total SK dose was given to all subjects over 40.3±17.5 and 40.2±13.4 min for the placebo and lexipafant groups respectively. Peak and time integrals of creatine kinase were not different in the two groups. There were no adverse effects attributable to lexipafant. It is concluded that the PAF receptor antagonist lexipafant has no significant effect on SK-induced hypotension and does not facilitate an accelerated regimen of administration.

scholarly journals Receptor mechanisms of PAF mediated lymphatic constriction in the canine forelimb

1992 ◽  
Vol 1 (6) ◽  
pp. 391-395 ◽  
Author(s):  
D. E. Dobbins
Keyword(s):  
Smooth Muscle ◽  
Receptor Antagonist ◽  
Lymphatic Vessel ◽  
Perfusion Pressure ◽  
Muscle Tone ◽  
Platelet Activating Factor ◽  
Arterial Infusion ◽  
Paf Receptor ◽  
Transport Fluid ◽  
Paf Receptor Antagonist

Platelet activating factor (PAF) is a potent inflammatory lipid. In this study we assessed the ability of PAF to impact lymphatic vessel function by altering prenodal lymphatic resistance. Intralymphatic PAF (7.47 × 10−6, 7.47 × 10−5and 7.47 × 10−4M) increased lymphatic perfusion pressure at the two highest infusion rates. PAF mediated lymphatic constriction was not altered by the intra-arterial infusion of phentolamine but was blocked by the intra-arterial infusion of the PAF receptor antagonist WEB 2170. These data indicate that in addition to PAF's effects on microvascular permeability, this agent may also impact the ability of the lymphatics to transport fluid through alterations in lymphatic smooth muscle tone. PAF mediated lymphatic constriction is not mediated by α-receptors but rather through PAF receptor mediated mechanism.

Effect of platelet-activating factor (PAF) receptor antagonist (BN52021) on acetaminophen-induced acute liver injury and regeneration in rats

2005 ◽  
Vol 26 (1) ◽  
pp. 97-105 ◽  
Author(s):  
A. D. Grypioti ◽  
S. E. Theocharis ◽  
C. A. Demopoulos ◽  
Z. Papadopoulou-Daifoti ◽  
A. C. Basayiannis ◽  
...  
Keyword(s):  
Liver Injury ◽  
Receptor Antagonist ◽  
Acute Liver Injury ◽  
Platelet Activating Factor ◽  
Paf Receptor ◽  
Paf Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document